Navigation Links
New York Medicaid Program Establishes Coverage for Trofile(TM)
Date:4/8/2008

provided by patents, possible regulation of Trofile and our other products by the FDA, and activities expected to occur in connection with the Pfizer collaboration. These forward- looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that physicians may not use a molecular diagnostic for patient selection for maraviroc or other HIV drugs; risks related to the implementation of the collaboration with Pfizer; risks related to our ability to recognize revenue from activities under the collaboration with Pfizer; risks and uncertainties relating to the performance of our products; the growth in revenues; the size, timing and success or failure of any clinical trials for CCR5 inhibitors, entry inhibitors or integrase inhibitors; the risk that our Trofile Assay may not be utilized for patient use with maraviroc and other CCR5 inhibitors; our ability to establish reliable, high-volume operations at commercially reasonable costs; expected reliance on a few customers for the majority of our revenues; the annual renewal of certain customer agreements; actual market acceptance of our products and adoption of our technological approach and products by pharmaceutical and biotechnology companies; our estimate of the size of our markets; our estimates of the levels of demand for our products; the impact of competition; the timing and ultimate size of pharmaceutical company clinical trials; whether payers will authorize reimbursement for our products and services and the amount of such reimbursement that may be allowed; whether the FDA or any other agency will decide to further regulate our products or services, including Trofile; whether the draft guidance on Multivariate Index Assays issued by FDA will be subsequently determined to apply to
'/>"/>
SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. STAAR Surgicals Collamer(R) IOL Designated as a New Technology Intraocular Lens by the Centers for Medicare and Medicaid Services
2. AstraZeneca Response to February 21, 2008 Ruling In Re: Alabama Medicaid Pharmaceutical AWP Litigation - cv2005-219 - Circuit Court of Montgomery, Alabama
3. Change in Medicare and Medicaid Legislation Creates Market for Antimicrobial Coatings In the U.S.
4. UniCare Unveils Community Resource Center in Topeka to Serve Medicaid Enrollees
5. Open Biosystems Open Access RNAi Program Adopted by University of Copenhagen and University of Queensland
6. Schering-Plough Launches Productivity Transformation Program To Confront New Challenges
7. Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program
8. Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program
9. Diplomat Specialty Pharmacy Hires National Accounts Manager to Expand Multiple Sclerosis Program
10. Department of Defense Awards $5.8 Million Contract Modification Providing Additional Funding for PharmAthenes Protexia(R) Program
11. XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... Potential Efficacy in Huntington,s Disease Already Demonstrated, ... Pharmaceuticals,Corp. ("Raptor" or the "Company") (OTC Bulletin ... and Drug Administration ("FDA") has granted,orphan drug ... of Huntington,s disease ("HD"). Cysteamine is currently ...
... for Early Identification of High Risk Patients Early ... Intervention Can Help Prevent Disease Progression, SAN FRANCISCO, ... 68th Scientific Sessions of the American Diabetes Association,(ADA) that ... Diabetes,Risk Test, a first-of-its-kind predictive tool that delivers an ...
... June 6 Bioheart, Inc. (Nasdaq:,BHRT) will host its ... at Chispa Restaurant, located at 11500 NW 41st Street ... EASTERN., Interested parties may listen to the Bioheart, ... (domestic) or (706) 643-0580,(international). To listen to the Annual ...
Cached Biology Technology:Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease 2Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease 3Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease 4Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease 5Tethys Bioscience Announces Expanded Availability of PreDx(TM) Diabetes Risk Test 2Tethys Bioscience Announces Expanded Availability of PreDx(TM) Diabetes Risk Test 3Tethys Bioscience Announces Expanded Availability of PreDx(TM) Diabetes Risk Test 4Bioheart, Inc. to Host Annual Meeting of Shareholders on Wednesday, July 30, 2008 2
(Date:12/4/2014)... PALM BEACH GARDENS, Fla. , Dec. 3, ... identity management solutions, today announced that its DigitalPersona ... 4500 fingerprint readers have been deployed throughout ... Carolina , South Carolina ... network headquartered in Southern Pines, North ...
(Date:12/3/2014)... 2014 As part of our commitment to ... pleased to announce the release of a new reader ... the workforce data that they need. The ... by existing readers. Many such devices have serious shortcomings ... technology. Older models force users to navigate numerous complicated ...
(Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... York College, and one of the most prolific inventors ... that are transmitted from Smartphones to third party agencies. ... and has one of the earliest known patents in ... usage in the military, child care, elder care and ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... research team led by a Michigan State University professor has discovered ... help treat one of the disease,s most common and potentially blindness-causing ... to blood vessels in the retina that affects up to 80 ... in damage to the nerves found in bone marrow that leads ...
... report that Helicobacter pylori , the only bacterium ... human stomach, directly activates an enzyme in host cells ... including gastric cancer. Chronic infection with H. ... forms of gastric cancer, but researchers have not yet ...
... a growing number of fast food and chain restaurants display ... a study suggests some of this information may be unreliable. ... 18 side dishes and entrees from national sit-down chain restaurants, ... and 10 frozen meals purchased from supermarkets. They compared their ...
Cached Biology News:MSU researcher links diabetic complication, nerve damage in bone marrow 2Team finds link between stomach-cancer bug and cancer-promoting factor 2Team finds link between stomach-cancer bug and cancer-promoting factor 3Study examines calorie information from restaurants, packaged foods 2
... protein A media yield highly purified ... to analysis of other immunoglobulin classes, ... purification. Protein A binds to the ... from mammalian species. This ready-to-use, bottled ...
... bis- (3-D-Gluconamidopropyl)deoxycholamide White solid. HYGROSCOPIC. ... CHAPSO. Has reduced electrostatic interactions that do ... DEAE-cellulose. Aggregation number: 8-16. Purity: ≥95% ... O. Aggregation number 8 - 16, CMC ...
Goat Anti-Horse IgG(T) Antibody, Unconjugated...
Goat polyclonal to STMN2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: AKTAMAYKEK, corresponding to C terminal amino acids 2-11 of STMN2. Entrez Gene ID: 11075 Swi...
Biology Products: